PT  - JOURNAL ARTICLE
AU  - Chandrasekar, Viveksandeep Thoguluva
AU  - Venkatesalu, Bhanuprasad
AU  - Patel, Harsh K.
AU  - Spadaccini, Marco
AU  - Manteuffel, Jacob
AU  - Ramesh, Mayur
TI  - A Systematic Review and Meta-analysis of Therapeutic options against SARS-CoV-2
AID  - 10.1101/2020.05.20.20108365
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.20.20108365
4099  - http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108365.short
4100  - http://medrxiv.org/content/early/2020/05/23/2020.05.20.20108365.full
AB  - Importance Treatment options for Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) are limited with no clarity on the efficacy and safety profiles.Objective To assess if the effect estimate of any intervention improves the outcomes and safety profile.Data sources PubMed, Embase, Cochrane Central were searched from December 1, 2019 to May 11, 2020.Study selection Any prospective/retrospective clinical study on SARS-CoV-2 patients ≥18 years of age with report on therapeutic interventions.Data synthesis and extraction Data was screened and extracted by two independent investigators.Main outcomes and measures The primary outcome was all-cause in-hospital mortality. The secondary outcomes were rates of mechanical ventilation, viral clearance, adverse events, discharge, progression to severe disease, median time for clinical recovery and anti-viral clearance. Pooled rates and odds ratios (OR) were calculated.Results A total of 29 studies with 5207 participants were included in the analysis. The pooled all-cause in-hospital mortality rate was 12.8% (95%CI: 8.1%-17.4%) in intervention arm. There was no significant difference in mortality between both arms overall (OR: 1.36, 95% CI: 0.97-1.89). The mortality was significantly higher in the Hydroxychloroquine (HCQ) group compared to control: (1.86, 95% CI: 1.38 – 2.50). The need for mechanical ventilation in patients with mild-moderate disease was 13.5% vs 9.8% in intervention and control groups, with no significant difference (OR: 1.58, 95% CI: 0.60 – 4.15).The median duration for viral clearance in the intervention arm was 6.1 (IQR: 4.3 – 8.8) days and control arm was 9 (IQR: 4.5 – 14) days, with no significant difference between the groups (p = 0.37). There was no significant difference between pooled adverse event rates in intervention and control groups: 34% vs 29.5% (OR: 1.44, 95% CI: 0.70 – 2.94), respectively. However, incidence of adverse events was significantly higher in HCQ sub-group (OR: 3.88, 95% CI: 1.60 – 9.45, I2 = 0%). There was no significant difference in other secondary outcomes.Conclusion and relevance The use of hydroxychloroquine was associated with increased mortality and adverse event rates. No other therapeutic intervention including Lopinavir/Ritonavir, Remdesivir or Tocilizumab seem to alter the natural course of the disease. There is a further need for well-designed randomized clinical trials.Article summary line The use of hydroxychloroquine was associated with increased mortality and adverse event rates in Severe acute respiratory syndrome-related coronavirus-2 infection and other therapeutic interventions did not show any difference in outcomesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNo source of funding to declareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was needed for this study as this is a systematic review and no patient information was disclosedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript is original and was created by the authors involved in this manuscriptSARS-CoV-2 -Severe Acute Respiratory Syndrome related Coronavirus-2HCQ –HydroxychloroquineCOVID-19 –Coronavirus disease 2019PRISMA –Preferred Reporting Items for Systematic Reviews and Meta-AnalysesRCT –Randomized Controlled TrialsNNT –Number needed to treatNNH –Number needed to harmIQR –Interquartile rangeCI –Confidence intervalOR –Odds ratioNIH –National Institute of HealthFDA –Food and Drug AdministrationWHO –World Health Organization